Repligen Announces Agreement to Acquire ARTeSYN Biosolutions
Safe Harbor
R REPLIGEN
2
This presentation contains forward looking statements which are made pursuant to the safe harbor
provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties which may
cause our plans to change or actual results to differ materially from those anticipated. In particular,
unforeseen events outside of our control may adversely impact future results. Additional information
concerning these factors is discussed in our reports filed with the Securities and Exchange Commission
including recent Form 8-Ks and our most recent Annual Report on Form 10-K. The forward looking
statements in this presentation reflect management's current views and may become obsolete as a
result of new information, future events or otherwise. We may not update such forward looking
statements to reflect a change of events or circumstances that occur after the date hereof, except as
required by law. The industry and market data contained in this presentation are based on
management's own estimates, independent publications, government publications, reports by market
research firms or other published independent sources, and, in each case, are believed by management
to be reasonable estimates. Although we believe these sources are reliable, we have not independently
verified the information.View entire presentation